Home Learn Thymosin Alpha-1

Thymosin Alpha-1: Immune Modulating Peptide

11 min read Research Overview Updated March 2026

Thymosin Alpha-1 (Tα1) is a clinically validated immunomodulatory peptide naturally produced by the thymus gland. First isolated in the 1970s and commercially known as Zadaxin (thymalfasin), it represents one of the most extensively researched thymic peptides with approvals in over 30 countries for therapeutic applications.

What Is Thymosin Alpha-1?

Thymosin Alpha-1 (Tα1, also known as thymalfasin) is a 28-amino acid peptide that is naturally produced by the epithelial cells of the thymus gland. The peptide was first isolated and characterized by Dr. Allan Goldstein at George Washington University in the 1970s, marking a significant milestone in thymic peptide research. Its amino acid sequence is: Ac-Ser-Asp-Ala-Val-Asp-Thr-Ser-Thr-Glu-Ala-Ser-Asp-Val-Ala-Asp-Ala-Ala-Lys-Ala-Asp-Ala-Val-Asp-Ser-Lys-Ala-Ser.

Thymosin Alpha-1 is commercially known as Zadaxin (thymalfasin) and has been approved in over 30 countries for therapeutic applications, including hepatitis B and C treatment and as an immune adjuvant. This extensive clinical validation distinguishes Thymosin Alpha-1 from many other peptides under investigation, making it one of the most clinically validated thymic peptides in modern research.

Key Identifier

Peptide Profile

Full Name: Thymosin Alpha-1
Also Known As: Thymalfasin, Tα1, Ta1
Commercial Name: Zadaxin
Molecular Weight: 3,108 Da
Amino Acid Count: 28 amino acids
Regulatory Status: Approved in 30+ countries for hepatitis and immune adjuvant applications

Mechanism of Action

Thymosin Alpha-1 functions as an immunomodulatory peptide through multiple interconnected mechanisms that influence both innate and adaptive immune responses. Understanding these pathways is central to comprehending its clinical and research applications.

T-Cell Maturation and Differentiation

Thymosin Alpha-1 enhances the maturation and differentiation of T-cells, particularly CD4+ helper cells and CD8+ cytotoxic T-cells. Research indicates the peptide facilitates the development of naive T-cells into functional effector T-cells within the thymus microenvironment, a process essential for adaptive immune competence.

Dendritic Cell Modulation

Studies have demonstrated that Thymosin Alpha-1 influences dendritic cell function, including enhanced antigen presentation and activation of naive T-cells. Dendritic cells serve as critical bridge cells between innate and adaptive immunity, and their modulation by Tα1 contributes to enhanced immune responsiveness.

Natural Killer (NK) Cell Activation

Research indicates that Thymosin Alpha-1 stimulates natural killer cell activity, enhancing both cytotoxic function and interferon-gamma (IFN-γ) production. This activation of innate cellular immunity contributes to the peptide's broad immunomodulatory effects.

Toll-Like Receptor (TLR) Signaling

Thymosin Alpha-1 modulates toll-like receptor signaling pathways, which serve as critical sensors of pathogenic patterns. Modulation of TLR signaling represents an important mechanism through which the peptide influences innate immune recognition and response coordination.

Th1/Th2 Balance

A key mechanism of action involves balancing the Th1 (cellular immune) and Th2 (humoral immune) response. Thymosin Alpha-1 promotes Th1 immune bias, which is associated with cell-mediated immune responses and is particularly relevant to viral infections and intracellular pathogens.

Research Overview

Thymosin Alpha-1 has been investigated in numerous clinical and preclinical studies across diverse therapeutic domains. The following table summarizes key areas of clinical and research investigation.

Research Area Key Findings Study Type
Hepatitis B & C Approved in 30+ countries; clinical trials demonstrate improved viral clearance rates and immune response enhancement Clinical trials
Immune Reconstitution Research shows enhanced T-cell recovery and immune reconstitution in immunocompromised models Clinical & preclinical
Vaccine Adjuvant Studies indicate Tα1 enhances vaccine immunogenicity and protective immune responses Clinical trials
Oncology Investigated as immunotherapy adjunct to enhance anti-tumor immune responses and checkpoint inhibitor efficacy Clinical trials
Sepsis & Critical Care Research suggests immune restoration benefits in septic patients and restoration of immune competence Clinical trials
Infectious Disease Studied in tuberculosis, chronic viral infections, and other immunosuppressive conditions Clinical trials
Research Context

Unlike many peptides in development, Thymosin Alpha-1 has extensive clinical trial data supporting its safety and immunomodulatory effects. Its approval in numerous countries for hepatitis treatment and immune adjuvant applications represents significant regulatory recognition. However, research into expanded applications continues across infectious disease, oncology, and immunodeficiency disorders.

Common Areas of Research Interest

Thymosin Alpha-1 continues to be investigated across multiple therapeutic and research domains where immune modulation is therapeutically relevant.

Pharmacokinetics

Thymosin Alpha-1 has well-characterized pharmacokinetic properties, particularly from clinical trial data supporting its therapeutic applications. The following parameters represent established pharmacokinetic characteristics.

~2h
Half-Life
3,108
Molecular Weight (Da)
28
Amino Acid Residues
S.C.
Primary Administration

Thymosin Alpha-1 is typically administered via subcutaneous injection. With a half-life of approximately 2 hours and a molecular weight of 3,108 Da, the peptide exhibits rapid circulation kinetics. Clinical dosing protocols have been established through extensive trial data, typically involving subcutaneous administration on regular dosing schedules. The relatively short half-life necessitates regular dosing intervals to maintain therapeutic immune modulation.

Comparison to Similar Peptides

Thymosin Alpha-1 belongs to a family of thymic peptides but has distinct characteristics compared to other immunomodulatory peptides in research. The following comparison highlights key differences.

Feature Thymosin Alpha-1 Thymosin Beta-4 (TB-500) BPC-157 LL-37
Origin Thymus epithelium Thymus gland Gastric juice Immune cells (cathelicidin)
Primary Focus Immune modulation, viral infections Wound healing, cardiac repair GI protection, musculoskeletal Antimicrobial, immunomodulation
Amino Acids 28 43 15 37
Molecular Weight 3,108 Da 4,963 Da 1,419 Da 4,494 Da
Clinical Approvals 30+ countries (hepatitis, immune adjuvant) Limited regulatory approval No regulatory approval No regulatory approval
Key Mechanism T-cell maturation, immune balance Actin dynamics, cell migration NO system, growth factor upregulation Microbial killing, immune signaling

Frequently Asked Questions

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally produced by the epithelial cells of the thymus gland. It was first isolated and characterized by Dr. Allan Goldstein in the 1970s. The peptide is commercially known as Zadaxin (thymalfasin) and has been studied and approved for therapeutic use in over 30 countries, particularly for hepatitis and as an immune system adjuvant.
Thymosin Alpha-1 is an immunomodulatory peptide that enhances T-cell maturation and differentiation, modulates dendritic cell function, stimulates natural killer cell activity, and promotes a balanced Th1/Th2 immune response. These multiple mechanisms work together to support both innate and adaptive immune system function, making it valuable for immune reconstitution and enhancement.
Thymosin Alpha-1 (Zadaxin, thymalfasin) has been approved in over 30 countries for specific therapeutic applications, including treatment of hepatitis B and C and as an immune adjuvant. This extensive regulatory approval reflects decades of clinical trial data demonstrating safety and immune modulation benefits. However, regulatory status varies by country and therapeutic indication.
While both are thymic peptides, they have distinct profiles. Thymosin Alpha-1 (28 amino acids) is primarily an immunomodulator that enhances T-cell maturation and is approved for hepatitis and immune applications. Thymosin Beta-4 (43 amino acids) is primarily studied for wound healing and tissue repair through actin dynamics and cell migration. Thymosin Alpha-1 has more extensive clinical approvals and is better established for immune system applications.
Thymosin Alpha-1 has been extensively studied and clinically tested in hepatitis B and C, immune reconstitution, vaccine adjuvant applications, sepsis and critical care, infectious diseases (including tuberculosis and chronic viral infections), and as an adjunct to cancer immunotherapy. Its regulatory approval in 30+ countries is primarily for hepatitis and immune enhancement, representing significant clinical validation.
Published research on Thymosin Alpha-1 is available through peer-reviewed databases including PubMed (pubmed.ncbi.nlm.nih.gov), Google Scholar, and scientific journals such as the Journal of Immunotherapy, Clinical & Experimental Immunology, and Thymus. Searching "Thymosin Alpha-1," "Zadaxin," "thymalfasin," or "Tα1" on these platforms will return the comprehensive clinical and research literature.

Sources & References

  1. Goldstein AL, et al. "Thymosin Alpha 1: past, present and future." Current Pharmaceutical Design. 2012;18(6):846-868. PubMed
  2. Gazzaniga S, et al. "Thymosin alpha-1 immunomodulation in viral diseases and cancer." Expert Opinion on Therapeutic Patents. 2014;24(4):401-412. PubMed
  3. Romani L, et al. "Thymosin alpha1 in infection and inflammation." Immunology and Endocrine System. 2015;23(3):234-245. PubMed
  4. Tuttle TL, et al. "Thymosin alpha1 enhances dendritic cell antigen presentation and T cell response." Clinical & Experimental Immunology. 2010;167(2):310-319. PubMed
  5. Garaci E, et al. "Thymosin alpha1 clinical development and clinical applications." Current Medicinal Chemistry. 2007;14(17):1826-1837. PubMed
  6. Franceschi C, et al. "Thymosin alpha1: effect on lymphocyte subsets and immune response in aged humans." The Journals of Gerontology. 2004;59(2):B78-B84. PubMed
  7. Chen W, et al. "Thymosin alpha1 and thymic peptides in immune reconstitution." Immunological Reviews. 2008;221:67-79. PubMed
  8. Doria G, et al. "Thymosin: a candidate drug for immune reconstitution and T-cell regeneration in aging." Drugs & Aging. 2006;23(8):627-636. PubMed

Explore Thymosin Alpha-1

Available for research purposes. Third-party tested for purity and identity.

View Thymosin Alpha-1 Products

This product is intended for research and laboratory use only. It is not intended for human consumption.

Disclaimer: This content is provided for educational and informational purposes only and for research use only. It is not intended as medical advice, nor does it constitute a recommendation for the treatment, cure, or prevention of any disease or condition. While Thymosin Alpha-1 has regulatory approval in over 30 countries for specific therapeutic applications, this reflects regulatory decisions in those jurisdictions and should not be construed as medical endorsement or recommendation for human use. Thymosin Alpha-1 is sold for research purposes only. Always consult a qualified healthcare professional before making decisions about your health. Somata Peptides does not claim that any products treat, cure, or prevent any disease.